- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05544513
Oral Iron Supplementation for Patients With Chronic Kidney Disease
Effects of Oral Iron Supplementation on Gut Microbiota in Patients With Chronic Kidney Disease
Study Overview
Status
Intervention / Treatment
Detailed Description
chronic kidney disease triggers several changes in the body, anemia is one of the first disorders that appear in chronic kidney disease patients. The anemia in this patient is multifactorial, the main cause being relative erythropoietin deficiency, although iron deficiency is also common. In this context, the need for oral iron supplementation is a way of both treating iron deficiency and optimizing the use of agents that stimulate erythropoiesis. However, this replacement can cause iron overload, increasing the production of reactive oxygen species and, consequently, oxidative stress, and also alter the intestinal microbiota leading to poor iron absorption, worsening the prognosis of chronic kidney disease. The current routine for iron supplementation for these patients is to offer oral iron daily, which can be more harmful than when given on alternate days. However, there are few studies comparing the two prescriptions.
In this context, since no study to date has been carried out to show the aforementioned effects in the participant with chronic kidney disease, this randomized clinical trial aims to assess the effects of daily or alternate-day oral iron supplementation on gut microbiota composition in participants with chronic kidney disease (glomerular filtration rate (GFR) below 30 mL/min) for 3 months. The project will also compare the effects of both prescriptions on serum hepcidin levels, markers of oxidative stress and inflammation, and on routine hematological and biochemical parameters.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
RJ
-
Rio de Janeiro, RJ, Brazil, 22260050
- Denise Mafra
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Aged 18 to 75 years Clinical diagnosis of Chronic Kidney Disease Conservative treatment group: chronic kidney disease stages 3 and 5
Exclusion Criteria:
- Patients pregnant
- Smokers
- Using antibiotics in the last 3 months
- Autoimmune diseases
- Clinical diagnosis of infectious diseases
- Clinical diagnosis of Cancer
- Clinical diagnosis of AIDS
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Group II
participants will receive one ferrous sulfate (120 mg of elemental iron) capsule daily (except on Sundays)
|
Participants will receive one ferrous sulfate (120 mg of elemental iron) capsule daily (except on Sundays)
|
Experimental: Group I
participants will receive one ferrous sulfate capsule (120 mg of elemental iron) on Mondays, Wednesdays and Fridays
|
Participants will receive one ferrous sulfate capsule (120 mg of elemental iron) on Mondays, Wednesdays and Fridays
|
Active Comparator: Group III
participants will receive one ferrous sulfate capsule (240mg of elemental iron) on Mondays, Wednesdays and fridays
|
Participants will receive one ferrous sulfate capsule (240mg of elemental iron) on Mondays, Wednesdays and fridays
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in cytokines plasma levels measured by ELISA after supplementation with oral iron
Time Frame: 2 months
|
cytokines plasma levels
|
2 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in uremic toxin plasma levels after supplementation with oral iron
Time Frame: 2 months
|
Get blood samples to evaluate the supplementation effects in uremic toxins such as indoxyl sulfate, p-cresyl sulfate
|
2 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Metabolic Diseases
- Urologic Diseases
- Disease Attributes
- Hematologic Diseases
- Renal Insufficiency
- Anemia, Hypochromic
- Iron Metabolism Disorders
- Chronic Disease
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Male Urogenital Diseases
- Kidney Diseases
- Renal Insufficiency, Chronic
- Anemia, Iron-Deficiency
- Kidney Failure, Chronic
- Anemia
- Dysbiosis
- Iron Deficiencies
Other Study ID Numbers
- DeniseMafra14
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dysbiosis
-
Experimental and Clinical Research CenterEnrolling by invitationGut Microbiota Dysbiosis and NutritionGermany
-
Jagiellonian UniversityCompletedMicrobiota, Cesarean Section, Probiotics, Dysbiosis
-
Copenhagen University Hospital, HvidovreCompletedTransplantation | Vaginal Dysbiosis | Vaginal MicrobiomeDenmark
-
Mucosa Innovations, S.L.Universidad de GranadaActive, not recruiting
-
International Centre for Diarrhoeal Disease Research...Bill and Melinda Gates FoundationRecruitingEnvironmental Enteric Dysfunction | Gut Microbiota DysbiosisBangladesh
-
National Taiwan University HospitalRecruitingGut Dysbiosis for TMAO Production From L-carnitine ConsumptionTaiwan
-
University of PalermoCompletedDysbiosis Symptoms Linked to PathologyItaly
-
Persephone BiosciencesActive, not recruiting
-
Sophie Bucher Della TorreUniversity Hospital, GenevaActive, not recruiting
-
University of California, DavisCompleted
Clinical Trials on Ferrous sulfate 3 days week
-
University of the Balearic IslandsNot yet recruiting
-
University of IoanninaCompletedSpinal Cord Injury/DamageGreece
-
Swiss Federal Institute of TechnologyUniversity of Oxford; St. Luke's Medical CenterTerminatedIron-deficiencyPhilippines
-
National Cardiovascular Center Harapan Kita Hospital...CompletedHeart Failure, Systolic | Iron-deficiency Anemia
-
Iowa State UniversityCompletedIron-deficiency | Iron Deficiency Anemia | Iron Deficiency Anemia Treatment | Iron Deficiency Anaemia Due to Dietary CausesUnited States
-
University Hospital, CaenUniversity Hospital, Rouen; University Hospital, Lille; Amiens University Hospital and other collaboratorsCompletedPhysical Activity | Type 2 DiabetesFrance
-
Duzce UniversityCompletedIron Deficiency Anemia | Subclinical HypothyroidismTurkey
-
Instituto de Desarrollo e Investigaciones Pediátricas...UnknownIron-deficiency | AnemiaArgentina
-
Indiana UniversityCompletedAutosomal Dominant Hypophosphatemic RicketsUnited States
-
Swiss Federal Institute of TechnologyUniversity Hospital, Zürich; ETH ZurichCompletedAnemia | Iron Deficiency Anemia | Iron DeficiencySwitzerland